Cyheptamide

Cyheptamide
Clinical data
Other namesCyheptamine
Identifiers
  • tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.027.792
Chemical and physical data
FormulaC16H15NO
Molar mass237.302 g·mol−1
3D model (JSmol)
  • C1CC2=CC=CC=C2C(C3=CC=CC=C31)C(=O)N
  • InChI=1S/C16H15NO/c17-16(18)15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)15/h1-8,15H,9-10H2,(H2,17,18)
  • Key:APBVLLORZMAWKI-UHFFFAOYSA-N

Cyheptamide was a investigational new drug that was developed by Ayerst Research Laboratories in the 1960s and was evaluated as an anticonvulsant.[1]

Cyheptamide undergoes significant metabolic transformation in both animals and humans, primarily through hydroxylation pathways.[2]

Cyheptamide exhibits moderate acute toxicity in animal models, with species-specific variations in lethal dose values.[3]


References

  1. ^ "Cyheptamide". Inxight: Drugs. NCATS. Retrieved 2025-06-25.
  2. ^ Kraml M, Sestanj K, Dvornik D (September 1971). "Metabolism of the anticonvulsant 10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-carboxamide. I. Metabolic fate of (14C)cyheptamide in animals and man". Biochemical Pharmacology. 20 (9): 2327–2338. doi:10.1016/0006-2952(71)90232-2. PMID 5163146.
  3. ^ van Eeken CJ, Birtwhistle RD, Mulder D (November 1970). "Toxicological study of cyheptamide: 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carboxamide (BS 7029)". Archives Internationales de Pharmacodynamie et de Therapie. 188 (1): 79–85. PMID 5485105.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.